AbbVie Skids On Mixed Earnings Report, Narrowed 2022 Earnings ViewInvestors Business Daily • 10/28/22
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)Business Wire • 10/28/22
AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (LBCL)PRNewsWire • 10/28/22
AbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific MeetingPRNewsWire • 10/24/22